$1.5M CEO Buy After $722K CFO. Cluster Forming.
Second major insider buy on Summit Therapeutics today. The CEO just dropped $1.46 million at $14.60 after his CFO put up $722K this morning. That's $2.2 million in C-suite conviction in one day, right above RSI oversold territory at 36. Technicals are brutal across all timeframes, but insiders on this biotech name have been right 64% of the time historically.
The Filing
| Ticker | SMMT |
| Company | Summit Therapeutics Inc. |
| Insider | Mahkam Zanganeh, Co-Chief Executive Officer |
| Buy amount | $1.5M |
| Filing date | June 4, 2026 |
| Conviction | Interesting · 61/100 |
| Setup type | Oversold Bounce |
Ultimate members received this analysis in real time.